ACRV
Acrivon Therapeutics, Inc. Common Stock
Nasdaq · usd
Acrivon Therapeutics, Inc. Common Stock (ACRV) trades at $1.15 (-17.90%) as of 4:10:04 PM EST on Nov 20, 2026, -34.66% over the past month. Market cap is $60.08M, with 11.4 days to cover in short interest.
Stock performance
How Acrivon Therapeutics, Inc. Common Stock (ACRV) stock has performed from one day to one year, with its 52-week range.
- 1D
- -17.86%
- 1W
- -20.69%
- 1M
- -34.66%
- YTD
- -52.28%
- 1Y
- -50.00%
- 52-wk range
- $0.97 – $3.56
Key statistics
Today's trading snapshot for ACRV: day range, open, previous close, volume and market cap.
- Day range
- $0.97 – $1.40
- Open
- $1.40
- Prev close
- $1.40
- Volume
- 1.29M
- Market cap
- $60.08M
- Shares out
- 42.85M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Acrivon Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 0.95
- P/FCF
- —
- ROE
- -104.4%
- ROA
- -86.2%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 18, 2026
8-K filings
Material corporate events Acrivon Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 16, 2026
On November 16, 2026, Acrivon Therapeutics, Inc., or the Company, issued a press release announcing its financial results for the quarter ended September 30, 2026, and providing business updates.
- Business updateNov 10, 2026
The webcast ... [was] to discuss Acrivon's new immunology and inflammation (I&I) programs, acquired using its AI-driven AP3 platform, including the ACR-525 and PKCθ inhibitor preclinical programs and initial development plans in EoE.
- Asset purchase or saleNov 6, 2026
As consideration for the transfer of the Acquired Assets, the Company has paid cash, and the Company has no obligation to make additional payments, including milestone or royalty payments, in respect of the Transaction.
- Equity compensation grantJun 17, 2026
The stockholders approved the Acrivon Therapeutics, Inc. Amended and Restated 2022 Equity Incentive Plan. Subject to the terms and conditions of the Amended and Restated 2022 Plan, the aggregate number of shares of the Company's common stock that may be issued pursuant to awards granted under the Amended and Restated 2022 Plan is 8,606,723 shares, which includes an increase of 3,000,000 shares approved by the Company's stockholders at the Annual Meeting.
- Investor presentationMar 19, 2026
The Company posted to the "Investors & Media" section of the Company's website at ir.acrivon.com, a corporate presentation providing an update on the Company's business (the "Corporate Presentation").
ACRV short interest
How heavily ACRV is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 11.4
- Short interest
- 1.8M
- Avg volume
- 158.68K
As of · reported to FINRA twice monthly.
ACRV news
The latest news and headlines about Acrivon Therapeutics, Inc. Common Stock (ACRV).
- Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion ABpositiveGlobeNewswire Inc.· Nov 6, 2026
- Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development OpportunitiespositiveGlobeNewswire Inc.· Apr 17, 2026
- Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint InhibitorspositiveGlobeNewswire Inc.· Mar 17, 2026
- Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsightpositiveGlobeNewswire Inc.· Jul 15, 2025
- Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data AnalysispositiveGlobeNewswire Inc.· Sep 14, 2024
Frequently asked questions
What is the Acrivon Therapeutics, Inc. Common Stock (ACRV) stock price today?
Acrivon Therapeutics, Inc. Common Stock (ACRV) is trading at $1.15 (-17.90% on the day) as of 4:10:04 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Acrivon Therapeutics, Inc. Common Stock?
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification…
What is the short interest in ACRV?
As of Oct 30, 2026, ACRV has 1.8M shares short and 11.4 days to cover.
What exchange is ACRV listed on?
Acrivon Therapeutics, Inc. Common Stock (ACRV) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of ACRV with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ACRV analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.